EP0484106A1
(fr)
*
|
1990-11-01 |
1992-05-06 |
Merck & Co. Inc. |
Compositions à libération contrôlée
|
US6764697B1
(en)
*
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
DE4140194C2
(de)
*
|
1991-12-05 |
1998-02-19 |
Alfatec Pharma Gmbh |
Ein Dihydropyridinderivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
DE59303759C5
(de)
*
|
1992-01-17 |
2009-04-09 |
Alfatec-Pharma Gmbh |
Wirkstoff-enthaltende festkörper mit einem gerüst aus hydrophilen makromolekülen und verfahren zu ihrer herstellung
|
US5582837A
(en)
*
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
ATE173159T1
(de)
*
|
1992-03-25 |
1998-11-15 |
Depomed Systems Inc |
Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
|
US5614212A
(en)
*
|
1992-04-08 |
1997-03-25 |
International Medical Associates, Inc. |
Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
|
US5922340A
(en)
*
|
1992-09-10 |
1999-07-13 |
Children's Medical Center Corporation |
High load formulations and methods for providing prolonged local anesthesia
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
JPH08507747A
(ja)
*
|
1992-12-30 |
1996-08-20 |
クローバー コンソリデイテッド,リミテッド |
生物学的活性物質用の細包を保護し生体に適合する、再利用可能なマクロカプセル封入システム
|
IL119660A
(en)
*
|
1993-05-10 |
2002-09-12 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US6726930B1
(en)
|
1993-09-09 |
2004-04-27 |
Penwest Pharmaceuticals Co. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US5773025A
(en)
|
1993-09-09 |
1998-06-30 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems--amorphous drugs
|
US5455046A
(en)
*
|
1993-09-09 |
1995-10-03 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US5662933A
(en)
*
|
1993-09-09 |
1997-09-02 |
Edward Mendell Co., Inc. |
Controlled release formulation (albuterol)
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
CN1108150C
(zh)
*
|
1994-05-13 |
2003-05-14 |
史密丝克莱恩比彻姆公司 |
增加钙摄取的方法及所用的制剂
|
GB2292079B
(en)
*
|
1994-08-12 |
1998-07-15 |
Flexpharm Ltd |
Coated prednisolone preparation for the treatment of inflamatory bowel disease
|
GB9422154D0
(en)
*
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US5538737A
(en)
*
|
1994-11-30 |
1996-07-23 |
Applied Analytical Industries, Inc. |
Oral compositions of H2 -antagonists
|
US5942241A
(en)
|
1995-06-09 |
1999-08-24 |
Euro-Celtique, S.A. |
Formulations and methods for providing prolonged local anesthesia
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
JPH11511763A
(ja)
|
1996-06-24 |
1999-10-12 |
ユーロ―セルティーク,エス.エイ. |
安全な局所麻酔の提供方法
|
KR100321489B1
(ko)
|
1996-07-08 |
2002-10-09 |
에드워드 멘델 컴파니 인코포레이티드 |
고용량의불용성약물용서방성매트릭스
|
US6046187A
(en)
*
|
1996-09-16 |
2000-04-04 |
Children's Medical Center Corporation |
Formulations and methods for providing prolonged local anesthesia
|
US5972389A
(en)
*
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
US5788987A
(en)
*
|
1997-01-29 |
1998-08-04 |
Poli Industria Chimica Spa |
Methods for treating early morning pathologies
|
US5891474A
(en)
*
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
US5837379A
(en)
*
|
1997-01-31 |
1998-11-17 |
Andrx Pharmaceuticals, Inc. |
Once daily pharmaceutical tablet having a unitary core
|
US5922352A
(en)
*
|
1997-01-31 |
1999-07-13 |
Andrx Pharmaceuticals, Inc. |
Once daily calcium channel blocker tablet having a delayed release core
|
US20030124187A1
(en)
*
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
US7179486B1
(en)
|
1997-04-01 |
2007-02-20 |
Nostrum Pharmaceuticals, Inc. |
Process for preparing sustained release tablets
|
US6656508B2
(en)
*
|
1997-04-17 |
2003-12-02 |
Amgen Inc. |
Sustained-release alginate gels
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
PT998271E
(pt)
|
1997-06-06 |
2005-10-31 |
Depomed Inc |
Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
|
BR9815499A
(pt)
*
|
1997-07-02 |
2001-01-02 |
Euro Celtique Sa |
Anestesia prolongada nas juntas e nos espacos corporais.
|
DE19734538C1
(de)
*
|
1997-07-30 |
1998-12-24 |
Jenapharm Gmbh |
Bioadhäsive Tablette
|
EP1003476B1
(fr)
*
|
1997-08-11 |
2004-12-22 |
ALZA Corporation |
Forme galenique d'un agent actif a liberation prolongee adaptee a la retention gastrique
|
IN186245B
(fr)
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
US6056977A
(en)
*
|
1997-10-15 |
2000-05-02 |
Edward Mendell Co., Inc. |
Once-a-day controlled release sulfonylurea formulation
|
US6485748B1
(en)
|
1997-12-12 |
2002-11-26 |
Andrx Pharmaceuticals, Inc. |
Once daily pharmaceutical tablet having a unitary core
|
EP2332522A3
(fr)
|
1998-03-19 |
2011-12-07 |
Bristol-Myers Squibb Company |
Système d'apport à libération lente biphasique destiné à des médicaments à solubilité elevée et procédé associé
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
EP0978285B1
(fr)
|
1998-08-07 |
2005-11-23 |
F. Hoffmann-La Roche Ag |
Compositions pharmaceutiques stables contenant des protéines Hedgehog, et leur utilisation
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
US6635281B2
(en)
|
1998-12-23 |
2003-10-21 |
Alza Corporation |
Gastric retaining oral liquid dosage form
|
US6878386B1
(en)
|
1999-04-13 |
2005-04-12 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
|
US7250176B1
(en)
*
|
1999-04-13 |
2007-07-31 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection
|
US6294199B1
(en)
*
|
1999-04-13 |
2001-09-25 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising administering amoxycillin
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
IL143375A0
(en)
*
|
1999-09-30 |
2002-04-21 |
Penwest Pharmaceuticals Co |
Sustained release matrix systems for highly soluble drugs
|
KR101476574B1
(ko)
|
1999-10-29 |
2014-12-24 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
DE10014588A1
(de)
|
2000-03-27 |
2001-10-04 |
Basf Ag |
Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
|
US6881420B2
(en)
|
2000-06-23 |
2005-04-19 |
Teva Pharmaceutical Industries Ltd. |
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
DE10031043A1
(de)
*
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
US20060099245A1
(en)
*
|
2000-08-01 |
2006-05-11 |
Manoj Kumar |
Hydrodynamically balancing oral drug delivery system with biphasic release
|
US6756057B2
(en)
|
2000-10-12 |
2004-06-29 |
Beecham Pharmaceuticals (Pte) Limited |
Amoxicillin and potassium clavulanate dosage form
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
MXPA03003895A
(es)
|
2000-10-30 |
2003-07-28 |
Euro Celtique Sa |
Formulaciones de hidrocodona de liberacion controlada.
|
WO2002058670A1
(fr)
*
|
2001-01-25 |
2002-08-01 |
Euroceltique S.A. |
Anesthesie locale, et procede d'utilisation
|
IL157634A0
(en)
*
|
2001-03-13 |
2004-03-28 |
Penwest Pharmaceuticals Co |
Chronotherapeutic dosage forms containing glucocorticosteroid
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
CA2409552A1
(fr)
*
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Forme posologique orale pouvant etre retenue dans l'estomac dont la liberation est limitee a la partie inferieure du tube digestif
|
US7612112B2
(en)
*
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
WO2003035039A1
(fr)
*
|
2001-10-25 |
2003-05-01 |
Depomed, Inc. |
Traitement utilisant une dose posologique de losartan a retention gastrique
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
US20030104052A1
(en)
*
|
2001-10-25 |
2003-06-05 |
Bret Berner |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US20070184104A1
(en)
*
|
2001-10-25 |
2007-08-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
EP1485078B1
(fr)
*
|
2002-03-15 |
2012-09-26 |
Cypress Bioscience, Inc. |
Milnacipran pour le traitement du syndrôme du colon irritable
|
US6930119B2
(en)
*
|
2002-07-17 |
2005-08-16 |
Reliant Pharmaceuticals, Inc. |
Liquid pharmaceutical composition
|
US8679533B2
(en)
*
|
2002-07-25 |
2014-03-25 |
Pharmacia Corporation |
Pramipexole once-daily dosage form
|
US20050232995A1
(en)
*
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
US20050208132A1
(en)
*
|
2002-07-29 |
2005-09-22 |
Gayatri Sathyan |
Methods and dosage forms for reducing side effects of benzisozazole derivatives
|
WO2004019907A1
(fr)
*
|
2002-08-29 |
2004-03-11 |
Activbiotics, Inc. |
Procedes et reactifs pour le traitement d'infections du clostridium difficile et de maladies qui lui sont associees
|
US20040220153A1
(en)
*
|
2002-09-24 |
2004-11-04 |
Jost-Price Edward Roydon |
Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
|
US20060003004A1
(en)
*
|
2002-10-25 |
2006-01-05 |
Collegium Pharmaceutical, Inc. |
Pulsatile release compositions of milnacipran
|
US20040132826A1
(en)
*
|
2002-10-25 |
2004-07-08 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
US20040086566A1
(en)
*
|
2002-11-04 |
2004-05-06 |
Alpharma, Inc. |
Waxy matrix dosage forms
|
WO2004056343A1
(fr)
*
|
2002-12-19 |
2004-07-08 |
Polymorfix, Inc. |
Formulations ingerables pour la reduction transitoire non invasive du volume gastrique
|
BRPI0406749A
(pt)
|
2003-01-13 |
2005-12-20 |
Dynogen Pharmaceuticals Inc |
Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
|
AU2004207578B2
(en)
*
|
2003-01-28 |
2007-06-28 |
Collegium Pharmaceutical, Inc. |
Multiparticulate compositions of milnacipran for oral administration
|
KR20040076203A
(ko)
*
|
2003-02-24 |
2004-08-31 |
주식회사 엘지생명과학 |
음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
BRPI0414311A
(pt)
*
|
2003-09-19 |
2008-03-04 |
Penwest Pharmaceutical Co |
formas de dosagem de liberação controlada
|
MXPA06003101A
(es)
*
|
2003-09-19 |
2006-06-20 |
Penwest Pharmaceuticals Co |
Formas de dosis cronoterapeuticas.
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
AU2004285533A1
(en)
*
|
2003-10-31 |
2005-05-12 |
Alza Corporation |
Compositions and dosage forms for enhanced absorption
|
US8734850B2
(en)
*
|
2003-11-25 |
2014-05-27 |
Flamel Technologies |
Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
|
US20050137262A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Hu Patrick C. |
Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
|
EP1753398B1
(fr)
*
|
2004-06-10 |
2018-09-19 |
Glatt Air Techniques, Inc. |
Formulation a dosage pharmaceutique contenant une matrice a liberation controlee
|
MXPA06014587A
(es)
*
|
2004-06-17 |
2007-04-27 |
Forest Laboratories |
Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
|
KR20070050081A
(ko)
*
|
2004-08-13 |
2007-05-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
|
KR101052436B1
(ko)
*
|
2004-08-13 |
2011-07-29 |
베링거 인겔하임 인터내셔날 게엠베하 |
프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도
|
US20060094760A1
(en)
*
|
2004-11-04 |
2006-05-04 |
Fawzy Abdel A |
Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution
|
FR2878159B1
(fr)
*
|
2004-11-24 |
2008-10-17 |
Flamel Technologies Sa |
Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
|
WO2006113568A2
(fr)
*
|
2005-04-19 |
2006-10-26 |
Alza Corporation |
Combinaison de tramadol et de matieres renfermant la gabapentine
|
WO2006138227A1
(fr)
*
|
2005-06-16 |
2006-12-28 |
Forest Laboratories, Inc. |
Formulation de gouttes de memantine a liberation modifiee et immediate
|
US8252776B2
(en)
|
2007-04-02 |
2012-08-28 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US20080241235A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US8722650B1
(en)
|
2005-06-24 |
2014-05-13 |
Medicis Pharmaceutical Corporation |
Extended-release minocycline dosage forms
|
US9192615B2
(en)
|
2008-08-06 |
2015-11-24 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne and certain dosage forms thereof
|
US7919483B2
(en)
|
2005-06-24 |
2011-04-05 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne
|
US7541347B2
(en)
*
|
2007-04-02 |
2009-06-02 |
Medicis Pharmaceutical Coropration |
Minocycline oral dosage forms for the treatment of acne
|
US7544373B2
(en)
*
|
2007-04-02 |
2009-06-09 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US20080242642A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
WO2007002597A2
(fr)
|
2005-06-27 |
2007-01-04 |
Biovail Laboratories International S.R.L. |
Formulations a liberation modifiee d'un sel de bupropion
|
WO2007008752A2
(fr)
*
|
2005-07-07 |
2007-01-18 |
Farnam Companies, Inc. |
Compositions pharmaceutiques a liberation prolongee pour medicaments tres solubles dans l'eau
|
EP1919466B9
(fr)
|
2005-07-11 |
2012-05-16 |
Cortria Corporation |
Formulations pour le traitement des anormalites liees aux lipoproteines comprenant une statine et un derive de la methylnicotinamide
|
US20090214643A1
(en)
*
|
2005-07-19 |
2009-08-27 |
Franklin Amie E |
Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
|
US8778395B2
(en)
|
2005-08-11 |
2014-07-15 |
Andrx Labs, Llc |
Diltiazem controlled release formulation and method of manufacture
|
BRPI0615410A2
(pt)
*
|
2005-08-30 |
2013-02-13 |
Nicholas Piramal India Ltd |
composiÇço farmacÊutica de liberaÇço prolongada de metformina e processo para produÇço da mesma
|
JP2009511606A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法
|
EP1945198A4
(fr)
*
|
2005-10-14 |
2009-08-26 |
Lundbeck & Co As H |
Formulations pharmaceutiques stables contenant de l'escitalopram et du bupropion
|
US20090176882A1
(en)
*
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
JP2009522272A
(ja)
*
|
2005-12-30 |
2009-06-11 |
ミドルブルック ファーマスーティカルス,インコーポレイテッド |
薬剤送達のための胃内放出パルスシステム
|
WO2007090883A1
(fr)
*
|
2006-02-10 |
2007-08-16 |
Boehringer Ingelheim International Gmbh |
Formulation à libération prolongée
|
WO2007090881A2
(fr)
*
|
2006-02-10 |
2007-08-16 |
Boehringer Ingelheim International Gmbh |
Formulation a liberation modifiee
|
US9011930B2
(en)
*
|
2006-05-01 |
2015-04-21 |
Zycal Bioceuticals Healthcare Company, Inc. |
Nutritional supplement and use thereof
|
EP2068840A2
(fr)
*
|
2006-07-21 |
2009-06-17 |
LAB International SRL |
Système de délivrance hydrophobe empêchant les utilisations abusives
|
WO2008084698A1
(fr)
|
2006-12-28 |
2008-07-17 |
Astellas Pharma Inc. |
Composition pharmaceutique à libération entretenue de tacrolimus
|
JP5162134B2
(ja)
*
|
2007-01-22 |
2013-03-13 |
愛媛県 |
機能性材料の製造方法、機能性材料、シート状構造体、及び衛生製品
|
US20080241197A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline dosage forms for the treatment of acne
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CA2694602A1
(fr)
*
|
2007-07-27 |
2009-02-05 |
Depomed, Inc. |
Formes medicamenteuses de retention gastrique pulsatile
|
US20090130017A1
(en)
*
|
2007-11-19 |
2009-05-21 |
Searete Llc |
Targeted short-lived drug delivery
|
US20090246276A1
(en)
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
EP2280670A4
(fr)
*
|
2008-04-28 |
2012-08-01 |
Eatlittle Inc |
Unités de formation de bézoard en vue du contrôle du poids
|
US20090285865A1
(en)
*
|
2008-05-14 |
2009-11-19 |
Shalaby Shalaby W |
Palatable, solid oral formulations for male chemical sterilization
|
EP3239170B1
(fr)
|
2008-06-04 |
2019-03-20 |
Synergy Pharmaceuticals Inc. |
Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
|
EP3241839B1
(fr)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
|
AU2009281752B2
(en)
*
|
2008-08-15 |
2016-11-17 |
Depomed Inc. |
Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
|
US20110268666A1
(en)
*
|
2008-09-29 |
2011-11-03 |
Yissum Research Development Company of the Research University of Jerusalem, Ltd. |
Novel gastroretentive delivery system
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
US8828953B2
(en)
*
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
AR076341A1
(es)
|
2009-04-20 |
2011-06-01 |
Elcelyx Therapeutics Inc |
Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion
|
WO2010129686A1
(fr)
|
2009-05-05 |
2010-11-11 |
Vapogenix, Inc. |
Nouvelles formulations d'anesthésiques volatiles et procédés d'utilisation pour réduire l'inflammation
|
CA2783342A1
(fr)
*
|
2009-12-08 |
2011-06-16 |
Depomed, Inc. |
Compositions pharmaceutiques a temps de residence gastrique augmente utilisees pour une liberation prolongee de polypeptides
|
JP5849947B2
(ja)
|
2010-03-29 |
2016-02-03 |
アステラス製薬株式会社 |
放出制御医薬組成物
|
WO2011146611A1
(fr)
*
|
2010-05-18 |
2011-11-24 |
Abon Pharmaceuticals, Llc |
Système modifié d'administration de médicaments gastro-rétentifs pour des médicaments de type amines
|
AU2011289407B2
(en)
|
2010-08-11 |
2015-06-18 |
Philadelphia Health & Education Corporation |
Novel D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
BR112013009635A2
(pt)
|
2010-10-19 |
2016-07-12 |
Elcelyx Therapeutics Inc |
terapias à base de ligante de receptor quimiossensorial
|
WO2012078633A2
(fr)
|
2010-12-07 |
2012-06-14 |
Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene |
Méthodes d'inhibition de la métastase d'un cancer
|
BR112013017411B1
(pt)
|
2011-01-07 |
2022-03-22 |
Anji Pharma (Us) Llc |
Uso de uma composição compreendendo metformina ou um sal da mesma
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
US9561241B1
(en)
|
2011-06-28 |
2017-02-07 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for minocycline
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
TWI622578B
(zh)
|
2011-12-21 |
2018-05-01 |
諾維拉治療公司 |
B型肝炎抗病毒劑
|
AU2012363873B2
(en)
|
2012-01-06 |
2017-11-23 |
Anji Pharmaceuticals Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
WO2013158928A2
(fr)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Thérapies à base de ligand de récepteur chimiosensoriels
|
JP6397407B2
(ja)
|
2012-07-19 |
2018-09-26 |
ドレクセル ユニバーシティ |
細胞タンパク質ホメオスタシスを調節するためのシグマ受容体リガンド
|
WO2014026013A2
(fr)
|
2012-08-09 |
2014-02-13 |
Dynamis Therapeutics, Inc. |
Méthodes destinées à préserver ou à améliorer la santé, le bien-être et/ou une fonction physiologique chez un sujet
|
EP3756669A1
(fr)
|
2013-01-07 |
2020-12-30 |
The Trustees of the University of Pennsylvania |
Compositions pour l'utilisation pour traiter un lymphome à cellules t cutané
|
US9545446B2
(en)
|
2013-02-25 |
2017-01-17 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
CA2905435A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions utiles pour le traitement de troubles gastro-intestinaux
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
EP3878445A3
(fr)
|
2013-06-05 |
2021-10-27 |
Synchroneuron Inc. |
Formulations d'acamprosate, leurs procédés d'utilisation et combinaisons les comprenant
|
CN106414752A
(zh)
|
2013-07-02 |
2017-02-15 |
桉树脑有限责任公司 |
具有抗微生物活性的挥发性有机化合物制剂
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
EP3054969B1
(fr)
|
2013-10-10 |
2021-03-10 |
Bausch Health Ireland Limited |
Agonistes de guanylate cyclase utiles pour le traitement de troubles induits par les opioïdes
|
JP6932506B2
(ja)
|
2013-11-26 |
2021-09-08 |
イエール ユニバーシティ |
細胞透過組成物およびそれを用いる方法
|
EP3079692A4
(fr)
|
2013-12-09 |
2017-10-18 |
Thomas Jefferson University |
Nouveau procédé de traitement d'une maladie neurodégénérative chez un mammifère qui en a besoin
|
RU2565396C1
(ru)
*
|
2014-04-01 |
2015-10-20 |
Александр Александрович Кролевец |
Способ получения нанокапсул аспирина в альгинате натрия
|
WO2015157262A1
(fr)
|
2014-04-07 |
2015-10-15 |
Women & Infants Hospital Of Rhode Island |
Nouveux dérivés de 7-déshydrocholestérol et procédés les utilisant
|
US20170266112A1
(en)
|
2014-06-11 |
2017-09-21 |
Massachusetts Institute Of Technology |
Residence structures and related methods
|
CN106573015B
(zh)
|
2014-06-11 |
2021-11-26 |
麻省理工学院 |
肠溶弹性体
|
WO2016028753A1
(fr)
|
2014-08-20 |
2016-02-25 |
Yale University |
Nouvelles compositions et méthodes utiles pour traiter ou prévenir des maladies ou des troubles hépatiques et favoriser la perte de poids
|
KR101642193B1
(ko)
*
|
2014-10-13 |
2016-07-25 |
씨제이헬스케어 주식회사 |
메트포르민 서방성 제제 및 그의 제조방법
|
US9617230B2
(en)
|
2014-12-22 |
2017-04-11 |
Farmington Pharma Development |
Creatine prodrugs, compositions and methods of use thereof
|
KR20160105662A
(ko)
|
2015-02-27 |
2016-09-07 |
대원제약주식회사 |
에페리손과 펠루비프로펜을 함유하는 약제학적 조성물
|
CN107592803B
(zh)
|
2015-05-01 |
2021-01-22 |
麻省理工学院 |
可触发形状记忆感应装置
|
US10597368B2
(en)
|
2015-05-08 |
2020-03-24 |
Brown University |
Syringolin analogues and methods of making and using same
|
JP6995627B2
(ja)
|
2015-05-19 |
2022-02-04 |
イエール ユニバーシティ |
病的石灰化状態を治療するための組成物およびそれを使用する方法
|
US10829440B2
(en)
|
2015-06-12 |
2020-11-10 |
Brown University |
Antibacterial compounds and methods of making and using same
|
WO2017003822A1
(fr)
|
2015-06-30 |
2017-01-05 |
Galleon Pharmaceuticals, Inc. |
Nouveaux composés de modulation de régulation de respiration et leurs procédés de fabrication et d'utilisation
|
EP3364946A4
(fr)
|
2015-10-23 |
2019-06-26 |
Lyndra, Inc. |
Systèmes à demeure gastriques pour libération prolongée d'agents thérapeutiques et leurs procédés d'utilisation
|
WO2017075145A1
(fr)
|
2015-10-28 |
2017-05-04 |
Yale University |
Amides de quinoléine et leurs méthodes d'utilisation
|
US20180371434A1
(en)
|
2015-11-20 |
2018-12-27 |
Yale University |
Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
|
CN105418861B
(zh)
*
|
2015-12-10 |
2018-02-13 |
宁波大学 |
一种基于聚氨基酸分子交联水凝胶及其制备方法
|
JP2019506383A
(ja)
|
2016-01-11 |
2019-03-07 |
シナジー ファーマシューティカルズ インコーポレイテッド |
潰瘍性大腸炎を治療するための製剤および方法
|
MX2018011278A
(es)
|
2016-03-17 |
2019-07-08 |
Thiogenesis Therapeutics Inc |
Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
|
WO2017190001A1
(fr)
|
2016-04-29 |
2017-11-02 |
The Regents Of The University Of Colorado, A Body Corporate |
Composés et compositions utiles pour traiter ou prévenir le syndrome metabolique et methodes d'utilisation de ces derniers
|
AU2017298648B2
(en)
|
2016-07-18 |
2023-05-11 |
Pharmena S.A. |
1-methylnicotinamide for the treatment of diseases associated with C-reactive protein
|
US20210330599A1
(en)
|
2016-08-01 |
2021-10-28 |
University Of Rochester |
Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
|
US11390859B2
(en)
|
2016-08-05 |
2022-07-19 |
Yale University |
Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
|
WO2018045229A1
(fr)
|
2016-09-01 |
2018-03-08 |
Mebias Discovery Llc |
Urées substituées et leur procédés de préparation et d'utilisation
|
WO2018064630A1
(fr)
|
2016-09-30 |
2018-04-05 |
Lyndra, Inc. |
Systèmes de résidence gastrique permettant l'administration prolongée de médicaments de la classe de l'adamantane
|
KR102522060B1
(ko)
|
2016-11-07 |
2023-04-14 |
아뷰터스 바이오파마 코포레이션 |
치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법
|
US20180161279A1
(en)
|
2016-12-14 |
2018-06-14 |
Amgen Inc. |
Gastro-retentive modified release dosage forms for oprozomib and process to make thereof
|
EP3571196B1
(fr)
|
2017-01-19 |
2023-01-04 |
Temple University Of The Commonwealth System Of Higher Education |
Nouveaux aminothiazoles à substitution bicycloalkyle pontés et leurs procédés d'utilisation
|
US11098010B2
(en)
|
2017-03-21 |
2021-08-24 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
CN110753546B
(zh)
|
2017-04-17 |
2023-11-10 |
耶鲁大学 |
治疗或预防急性肺损伤的化合物、组合物和方法
|
WO2019023621A1
(fr)
|
2017-07-28 |
2019-01-31 |
Yale University |
Médicaments anticancéreux et leurs procédés de fabrication et d'utilisation
|
CN111527103A
(zh)
|
2017-09-08 |
2020-08-11 |
科罗拉多大学董事会,法人团体 |
用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
|
CN111683684A
(zh)
|
2017-09-20 |
2020-09-18 |
硫创治疗公司 |
用于治疗半胱胺敏感性病症的方法
|
EP3703724A1
(fr)
|
2017-11-02 |
2020-09-09 |
NatureCeuticals Sdn. Bhd. |
Extrait d'orthosiphon stamineus, formulations et leurs utilisations
|
WO2019104316A1
(fr)
|
2017-11-27 |
2019-05-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Composés, compositions et méthodes pour le traitement et/ou la prévention d'une maladie parodontale
|
CN111417620B
(zh)
|
2017-12-01 |
2023-08-25 |
奥特吉尼克斯制药公司 |
肌酸前药、其组合物以及使用方法
|
WO2019125184A1
(fr)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Utilisation de biomarqueur en thérapie du cancer
|
SG11202006994XA
(en)
|
2018-01-24 |
2020-08-28 |
Univ Rockefeller |
Antibacterial compounds, compositions thereof, and methods using same
|
EP3802524A1
(fr)
|
2018-05-29 |
2021-04-14 |
Cersci Therapeutics, Inc. |
Composés pour le traitement de la douleur, compositions les comprenant, et leurs procédés d'utilisation
|
WO2020074944A1
(fr)
|
2018-10-11 |
2020-04-16 |
Sanifit Therapeutics S.A. |
Phosphates d'inositol pour le traitement de la calcification ectopique
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
MX2021008966A
(es)
|
2019-01-30 |
2021-11-04 |
Sanifit Therapeutics S A |
Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.
|
US20200246317A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
US20200246316A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
US11524048B2
(en)
|
2019-05-09 |
2022-12-13 |
The Feinstein Institutes For Medical Research |
HMGB1 antagonist treatment of severe sepsis
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
EP3818983A1
(fr)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Composés de phosphate d'inositol pour une utilisation dans le traitement, l'inhibition de la progression ou la prévention de la calcification cardiovasculaire
|
WO2021127456A1
(fr)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Procédés d'inhibition de protéines réceptrices du facteur de croissance épidermique
|
MX2022015772A
(es)
|
2020-06-09 |
2023-05-19 |
Inozyme Pharma Inc |
Proteínas enpp1 o enpp3 solubles y sus usos.
|
AU2021396978A1
(en)
|
2020-12-08 |
2023-02-23 |
Ruminant Biotech Corp Limited |
Improvements to devices and methods for delivery of substances to animals
|
EP4015494A1
(fr)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Procédés de préparation de sels solubles de phosphates d'inositol
|
EP4036097A1
(fr)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Composés dérivés substitués de l'ip4-4,6
|
WO2024023360A1
(fr)
|
2022-07-29 |
2024-02-01 |
Sanifit Therapeutics, S.A. |
Composés substitués par ip5
|
WO2024023359A1
(fr)
|
2022-07-29 |
2024-02-01 |
Sanifit Therapeutics, S.A. |
Composés dérivés substitués en ip4-4,6 destinés à être utilisés dans le traitement, l'inhibition de la progression et la prévention de la calcification ectopique
|
WO2024052895A1
(fr)
|
2022-09-06 |
2024-03-14 |
Hadasit Medical Research Services And Development Ltd |
Combinaisons comprenant des psychédéliques pour le traitement de la schizophrénie et d'autres troubles neuropsychiatriques et neurologiques
|